Potent and selective inhibitor of VEGFR2 tyrosine kinase (IC50 value of 1 nM). Apatinib could also potently suppress the activities of RET, c-KIT and c-Src with IC50 values of 0.13, 0.429 and 0.53 μM, respectively. In vivo, apatinib alone and in combination with chemotherapeutic agents effectively inhibited the growth of several established human tumor xenograft models with little toxicity.

KEYWORDS: Apatinib | supplier | VEGFR2 inhibitor | Apatinib mesylate | YN968D1 | Rivoceranib mesylate | CAS [1218779-75-9] | [811803-05-1] | VEGF | VEGFR | Inhibitor | Receptors | Angiogenesis